In patients with cystic fibrosis (CF) lung damage secondary to chronic infection is the main
cause of death. Treatment of lung disease to reduce the impact of infection, inflammation …

Cost-of-illness studies, the systematic quantification of the economic burden of diseases on
the individual and on society, help illustrate direct budgetary consequences of diseases in …

Background Respiratory tract infections with Pseudomonas aeruginosa occur in most
people with cystic fibrosis (CF). Established chronic P aeruginosa infection is virtually …

Background Inhaled antibiotics are commonly used to treat persistent airway infection with
Pseudomonas aeruginosa that contributes to lung damage in people with cystic fibrosis …

Specifically formulated for nebulisation using the PARI LC PLUS™ reusable nebuliser,
tobramycin solution for inhalation (TSI)[TOBI®] provides a high dose of tobramycin (an …

Background: Geographic transferability of economic evaluation data from one country to
another has the potential to make a more efficient use of national and international …

Background Cystic fibrosis is a genetic disorder in which abnormal mucus in the lungs is
associated with susceptibility to persistent infection. Pulmonary exacerbations are when …

Repeated bouts of acute and chronic lung infections are responsible for progressive
pulmonary function decline in individuals with cystic fibrosis (CF), ultimately leading to …

European consensus guidelines recommend nebulised antibiotics for maintenance therapy
in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection. Two …

Background: Cystic fibrosis is the most common incurable hereditary disease in the US.
Persistent respiratory infection is the leading cause of morbidity and mortality in cystic …